CMV pp65 peptide
Term · Oncology and biomedicine · MLC-T-ONC-012677
A peptide derived from cytomegalovirus (CMV) internal matrix protein pp65. CMV pp65 peptide antigen is used in recombinant vaccinia virus as an HLA-A-restricted epitope to produce vaccines and specific CD8+ and CD4+ cell responses against CMV infection, a serious complication of allogeneic bone marrow transplantation (BMT). In BMT, CMV infection may be prevented by passive immunization with donor-derived CMV-pp65-specific T-cell clones if provided early post-BMT.
| Identifier | MLC-T-ONC-012677 |
|---|---|
| Field | Oncology and biomedicine |
| Abbreviation | CMV-PEP |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-012677",
"term": "CMV pp65 peptide",
"field": "Oncology and biomedicine",
"definition": "A peptide derived from cytomegalovirus (CMV) internal matrix protein pp65. CMV pp65 peptide antigen is used in recombinant vaccinia virus as an HLA-A-restricted epitope to produce vaccines and specific CD8+ and CD4+ cell responses against CMV infection, a serious complication of allogeneic bone marrow transplantation (BMT). In BMT, CMV infection may be prevented by passive immunization with donor-derived CMV-pp65-specific T-cell clones if provided early post-BMT.",
"abbreviation": "CMV-PEP",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/cmv-pp65-peptide/"
}
Record 5,024 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.